Clinical Trials

43 enrolled

Ovarian Neoplasms

NCT07355010 2026-01-21

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

104 enrolled

Ovarian Neoplasms

NCT07266350 2025-12-05

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer

Not yet recruiting

1,300 enrolled

Cervical Cancer Metastatic

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

120 enrolled

Cervical Cancer Metastatic

NCT05208177 2025-08-22

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Phase 2 Terminated

25 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

194 enrolled

Uterine Cervical Neoplasms, Recurrence

NCT05176080 2024-12-17

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Phase 1/2 Terminated

46 enrolled

Breast Neoplasms

NCT06516289 2024-12-12

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Phase 2 Recruiting

130 enrolled

BRCA-Mutated Breast Carcinoma

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

620 enrolled

Breast Neoplasms

NCT06336954 2024-03-29

Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure

40 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06332950 2024-03-27

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

80 enrolled

Small Cell Lung Carcinoma

NCT06306560 2024-03-12

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

40 enrolled

Small Cell Lung Carcinoma

NCT05999149 2024-02-21

BCTOP-T-N01

Phase 3 Recruiting

424 enrolled

Triple Negative Breast Neoplasms

NCT04409223 2024-02-09

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Phase 3 Terminated

185 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04395989 2023-12-22

FUTURE-SUPER

139 enrolled

Triple Negative Breast Neoplasms

NCT06146985 2023-11-28

Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

67 enrolled

Head & Neck

Thyroid Neoplasms

NCT04346381 2023-09-18

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

233 enrolled

Other solid neoplasm

Solid Tumor

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Phase 3 Terminated

1 enrolled

Advanced NSCLC

NCT04733417 2023-04-13

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

35 enrolled

Breast Neoplasms

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

450 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05051865 2022-11-17

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

60 enrolled

Dermatologic

Melanoma

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

265 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT04129996 2022-01-11

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

46 enrolled

Triple Negative Breast Neoplasms

NCT04479904 2021-06-22

A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Phase 2 Withdrawn

Cholangiocarcinoma

NCT04866381 2021-04-29

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

87 enrolled

Esophageal Squamous Cell Carcinoma

NCT02390947 2020-12-22

FACT

Phase 3 Completed

543 enrolled

Colorectal Neoplasms

NCT04044378 2020-05-19

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Phase 1/2 Withdrawn

Neoplasms, Disease Progression

NCT02356991 2019-11-04

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Suspended

137 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01392235 2019-01-22

Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

EndocrineGastrointestinalNET

58 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT01994213 2019-01-22

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Phase 2 Terminated

53 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT02766140 2019-01-18

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Phase 3 Terminated

12 enrolled

Non Squamous Non Small Cell Lung

NCT01829841 2018-05-03

A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

150 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT01762293 2018-04-18

A Study of Famitinib in Patients With Advanced Colorectal Cancer

154 enrolled

Colorectal Neoplasms

NCT02336724 2018-04-17

A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor